BioCentury
ARTICLE | Product Development

Deltanoid: Curiously strong

January 20, 2003 8:00 AM UTC

Deltanoid: Curiously strong

Osteoporosis represents a large market with room for improvement. All but one of the marketed drugs for the disease slow or stop bone loss, but do not promote new bone formation. Thus, Deltanoid Pharmaceuticals Inc. believes that its ability to mine an old vein - vitamin D analogs - can make it a player in the space. The company has preclinical data showing that its 2MD vitamin D analog stimulates bone formation in addition to preventing bone loss. ...